Retraction Note: SARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin (Nature Communications, (2016), 7, 1, (11996), 10.1038/ncomms11996);SARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin

Nature Communications

Volumn 7, Issue , 2016, Pages

  Dai, Lei ^a   Cui, Xueliang ^a   Zhang, Xin ^a   Cheng, Lin ^a   Liu, Yi ^a   Yang, Yang ^a   Fan, Ping ^b   Wang, Qingnan ^a   Lin, Yi ^a   Zhang, Junfeng ^a   Li, Chunlei ^a   Mao, Ying ^a   Wang, Qin ^a   Su, Xiaolan ^a   Zhang, Shuang ^a   Peng, Yong ^a   Yang, Hanshuo ^a   Hu, Xun ^b   Yang, Jinliang ^a   Huang, Meijuan ^b   Xiang, Rong ^c   Yu, Dechao ^a   Zhou, Zongguang ^b   Wei, Yuquan ^a   Deng, Hongxin ^a   more..

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c NANKAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; CERULOPLASMIN; PROTEINASE; VASCULOTROPIN; BATF2 PROTEIN, MOUSE; SARI PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARRAY; BIOASSAY; BLOOD; CANCER; CARCINOGEN; ENZYME ACTIVITY; GENE EXPRESSION; INHIBITION; INHIBITOR; MASS SPECTROMETRY; PROTEIN; TUMOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASSAY; CANCER PATIENT; CANCER PROGNOSIS; CARCINOGENESIS; COLON CANCER; CONTROLLED STUDY; ENZYME DEGRADATION; HUMAN; MASS SPECTROMETRY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; POLYACRYLAMIDE GEL ELECTROPHORESIS; TISSUE MICROARRAY; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; COLON TUMOR; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); TUMOR CELL LINE;

MUS;

ANIMALS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CERULOPLASMIN; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84976643510     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-023-40067-6     Document Type: Erratum

References (43)

1. Siegel, R., Naishadham, D., Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30 (2013).
2. McAuliffe, P. F., Cance, W. G. Preemptive surgery. Surgery 140, 1-5 (2006).
3. Smith, J. J., Deane, N. G., Dhawan, P., Beauchamp, R. D. Regulation of metastasis in colorectal adenocarcinoma: a collision between development and tumor biology. Surgery 144, 353-366 (2008).
4. Jonas, S. et al. Extended resections of liver metastases from colorectal cancer. World J. Surg. 31, 511-521 (2007).
5. Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666-2676 (2007).
6. Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501-513 (2011).
7. Ebos, J. M., Kerbel, R. S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8, 210-221 (2011).
8. Seymour, M. T. Adjuvant bevacizumab in colon cancer: where did we go wrong? Lancet Oncol. 13, 1176-1177 (2012).
9. Murphy, T. L., Tussiwand, R., Murphy, K. M. Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks. Nat. Rev. Immunol. 13, 499-509 (2013).
10. Finn, R. D. et al. The Pfam protein families database. Nucleic Acids Res. 38, D211-D222 (2010).
11. Dorsey, M. J. et al. B-ATF: a novel human bZIP protein that associates with members of the AP-1 transcription factor family. Oncogene 11, 2255-2265 (1995).
12. Iacobelli, M., Wachsman, W., McGuire, K. L. Repression of IL-2 promoter activity by the novel basic leucine zipper p21SNFT protein. J. Immunol. 165, 860-868 (2000).
13. Hildner, K. et al. Batf3 deficiency reveals a critical role for CD8alpha\+ dendritic cells in cytotoxic T cell immunity. Science 322, 1097-1100 (2008).
14. Ise, W. et al. The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells. Nat. Immunol. 12, 536-543 (2011).
15. Su, Z. Z. et al. Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN). Proc. Natl Acad. Sci. USA 105, 20906-20911 (2008).
16. Dash, R. et al. Inhibition of AP-1 by SARI negatively regulates transformation progression mediated by CCN1. Oncogene 29, 4412-4423 (2010).
17. Dash, R. et al. Novel mechanism of MDA-7/IL-24 cancer-specific apoptosis through SARI induction. Cancer Res. 74, 563-574 (2013).
18. Wang, C. et al. The function of SARI in modulating epithelial-mesenchymal transition and lung adenocarcinoma metastasis. PloS ONE 7, e38046 (2012).
19. Liu, Z. et al. BATF2 deficiency promotes progression in human colorectal cancer via activation of hgf/met signaling: a potential rationale for combining MET inhibitors with IFNs. Clin. Cancer Res. 21, 1752-1763 (2015).
20. Harned, J. et al. Ceruloplasmin alters intracellular iron regulated proteins and pathways: ferritin, transferrin receptor, glutamate and hypoxia-inducible factor-1alpha. Exp. Eye Res. 97, 90-97 (2012).
21. Chen, T. et al. Small GTPase RBJ mediates nuclear entrapment of MEK1/MEK2 in tumor progression. Cancer Cell 25, 682-696 (2014).
22. Neufert, C., Becker, C., Neurath, M. F. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat. Protoc. 2, 1998-2004 (2007).
23. Hanahan, D., Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
24. de Gramont, A. et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 13, 1225-1233 (2012).
25. Spannuth, W. A., Sood, A. K., Coleman, R. L. Angiogenesis as a strategic target for ovarian cancer therapy. Nat. Clin. Pract. Oncol. 5, 194-204 (2008).
26. Koh, Y. J. et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumour angiogenesis, metastasis, and vascular leakage. Cancer Cell 18, 171-184 (2010).
27. Radziwon-Balicka, A., Moncada de la Rosa, C., Zielnik, B., Doroszko, A., Jurasz, P. Temporal and pharmacological characterization of angiostatin release and generation by human platelets: implications for endothelial cell migration. PloS ONE 8, e59281 (2013).
28. Ferrara, N., Kerbel, R. S. Angiogenesis as a therapeutic target. Nature 438, 967-974 (2005).
29. Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6, 273-286 (2007).
30. Ferrara, N., Hillan, K. J., Gerber, H. P., Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400 (2004).
31. Stone, R. L., Sood, A. K., Coleman, R. L. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol. 11, 465-475 (2010).
32. Goel, H. L., Mercurio, A. M. VEGF targets the tumour cell. Nat. Rev. Cancer 13, 871-882 (2013).
33. Osaki, S., Johnson, D. A., Frieden, E. The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum. J. Biol. Chem. 241, 2746-2751 (1966).
34. Pan, Q. et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res. 62, 4854-4859 (2002).
35. Martin, F. et al. Copper-dependent activation of hypoxia-inducible factor (HIF)-1: implications for ceruloplasmin regulation. Blood 105, 4613-4619 (2005).
36. Mukhopadhyay, C. K., Mazumder, B., Fox, P. L. Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J. Biol. Chem. 275, 21048-21054 (2000).
37. Ma, H. et al. Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma. Int. J. Cancer 128, 771-777 (2011).
38. Wen, H. et al. Decreased expression of BATF2 is significantly associated with poor prognosis in oral tongue squamous cell carcinoma. Oncology Rep. 31, 169-174 (2014).
39. Cooper, R. A. et al. High tumor angiogenesis is associated with poorer survival in carcinoma of the cervix treated with radiotherapy. Clin. Cancer Res. 4, 2795-2800 (1998).
40. Inoshima, N. et al. The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. Clin. Cancer Res. 8, 3480-3486 (2002).
41. Najib, S. et al. Progastrin a new pro-angiogenic factor in colorectal cancer. Oncogene 34, 3120-3130 (2014).
42. Dai, L. et al. Plasmid-based STAT3-siRNA efficiently inhibits breast tumor growth and metastasis in mice. Neoplasma 58, 538-547 (2011).
43. Yu, D. C. et al. Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects. Mol. Ther. 20, 938-947 (2012).